Antoniu S A
Division of Pulmonary Disease, University of Medicine and Pharmacy Gr.T.Popa, Iasi, Romania.
Neth J Med. 2010 Aug;68(1):304-10.
Conventional therapies (corticosteroids, cytotoxic agents or interferon-a) or newer compounds such imatinib are used specifically in subsets of hypereosinophilic syndromes (HES). However other therapies are still needed in this condition.
To review the novel therapies for HES discussing their advantages and shortcomings.
Preclinical and clinical data on novel tyrosine kinase inhibitors, anti-IL -5 antibodies or anti-CD52 antibodies (alemtuzumab) are analysed. The former might represent appropriate options in case of imatinib resistance; the efficacy of anti-IL-5 monoclonal antibodies therapy is limited by the occurrence of rebound eosinophilia and alemtuzumab might be a promising anti-eosinophil therapy for all HES subsets.
Some of the novel therapies might become appropriate therapeutic options for HES.
传统疗法（皮质类固醇、细胞毒性药物或干扰素-α）或新型化合物如伊马替尼，专门用于嗜酸性粒细胞增多综合征（HES）的某些亚型。然而，这种情况下仍需要其他疗法。
综述HES的新型疗法，并讨论其优缺点。
分析了新型酪氨酸激酶抑制剂、抗IL-5抗体或抗CD52抗体（阿仑单抗）的临床前和临床数据。前者在伊马替尼耐药的情况下可能是合适的选择；抗IL-5单克隆抗体疗法的疗效受到嗜酸性粒细胞增多反弹的限制，而阿仑单抗可能是一种对所有HES亚型都有前景的抗嗜酸性粒细胞疗法。
一些新型疗法可能成为HES合适的治疗选择。
Zotero 插件